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Abstract. Homing of hematopoietic stem cells (HSC) to their microenvironment niches in the 
bone marrow is a complex process with a critical role in repopulation of the bone marrow after 
transplantation.  This active process allows for migration of HSC from peripheral blood and 
their successful anchoring in bone marrow before proliferation. The process of engraftment 
starts with the onset of proliferation and must, therefore, be functionally dissociated from the 
former process. In this overview, we analyze the characteristics of stem cells (SCs) with 
particular emphasis on their plasticity and ability to find their way home to the bone marrow. 
We also address the problem of graft failure which remains a significant contributor to 
morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). 
Within this context, we discuss non-malignant and malignant hematological disorders treated 
with reduced-intensity conditioning regimens or grafts from human leukocyte antigen (HLA)-
mismatched donors.  
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Introduction. Allogeneic hematopoietic stem cell 
transplantation (HSCT) currently represents one of 
the best standard treatment options for a variety of 
malignant and non-malignant hematological 
diseases. This approach is based on the ability of 
donor hematopoietic stem cells (HSC) to localize 
to recipient bone marrow (BM) niches. Notably, 
only a small percentage of infused HSCs (10%) 
engraft within the marrow microenvironment. This 
process, known as “Homing,” is not fully 
elucidated and our ability to modulate it remains 
incomplete. Engraftment failure is a rare but 
serious complication of HSCT. In order to gather 
the most robust evidence in this area, we 
performed a search of the literature available in 
Pubmed from January 2005 to January 2017 on 
"Hemopoietic stem cell homing and engraftment," 
"Hemopoietic stem cell homing and engraftment 
defects" and "Hemopoietic stem cell homing and 
chimerism." The present review covers the most 
important aspects of recent insights into the 
mechanisms of engraftment and defective 
engrafting activity of HSCs.  
 
Biological Properties of Stem Cells. Stem cells 
(SCs) are ancestral precursors common to all cell 
types. They are responsible for the generation of 
the tissues that form organs during embryogenesis 
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and from there on maintaining the capacity of self-
renewal for the entire life of the organism. The 
concept of stem cells dates back to the early 1960s 
when Till and McCulloch analyzed bone marrow 
to find out which components were responsible for 
in vivo blood regeneration.1 Ten days after 
transplantation of syngeneic bone marrow (BM) 
cells in a murine model, they observed the growth 
of nodules in the animal spleens. These nodules, 
defined by the authors as “spleen colonies,” 
appeared in proportion to the number of injected 
BM cells and were therefore thought to derive 
from a single BM cell.2 These preliminary 
observations made it possible to establish two 
main hallmarks of HSCs, namely, their ability to 
renew themselves (long-term self-renewal) and to 
give rise to mature cell types with characteristic 
morphology and specialized functions.  Before 
reaching a fully differentiated adult status, SCs 
generate intermediate cell types called precursors 
or progenitor cells. These cells are partially 
differentiated and committed to going through 
numerous cycles of cell division (committed 
precursors) to complete their developmental 
pathway in adult tissues.3 Experiments carried out 
on the Drosophila fruitfly suggest two different 
mechanisms by which SCs can simultaneously 
generate identical copies of themselves as well as 
more differentiated progeny.4 These two modes of 
cell division are referred to as asymmetric cell 
division and symmetric cell division. The first 
mode is characterized by an intrinsically 
asymmetric mechanism whereby only one of the 
two daughter cells inherit the regulating factors 
necessary for self-renewal and homeostatic control 
of the stem cell pool. Hence each single SC 
produces a copy of itself plus a differentiated cell 
(differentiative division).5-7  
In the second symmetric mode, homeostatic 
control is maintained at the population level rather 
than at single cell level.  Two types of symmetric 
division have been distinguished: a proliferative 
division which results in the generation of two 
new stem cells and a differentiation division which 
generates two differentiated cells.8  Several 
mathematical algorithms have been developed and 
are currently available for the simulation of stem 
cell proliferation kinetics.9 
SCs are classified as embryonic stem cells 
(ESCs), embryonic germ cells (EGCs) or adult 
stem cells (ACSs), depending on their origin and 
different properties. The cells that can virtually 
produce any kind of tissue in the body, including 
extra-embryonic and placental tissues, are known 
as totipotent cells. These totipotent zygote cells 
appear about 5-7 days after fertilization when the 
fertilized egg starts to divide and produces more 
totipotent stem cells. After about 4 days of cell 
division, these cells begin to specialize into 
pluripotent cells that can generate all embryonic 
tissues but not an entire organism.  That is why 
totipotent stem cells are considered the most 
versatile among the different types of SCs. 
ESCs and induced pluripotent stem cells 
(iPSCs) pertain to the category of pluripotent stem 
cells.  When pluripotent stem cells differentiate 
further, multipotent cells are formed, these cells 
are less plastic and more specialized and can 
develop into more than one cell type but never all 
types of cells of an organism or tissue. Examples 
of multipotent cells are HSCs and mesenchymal 
stem cells (MSCs). Oligopotent stem cells are 
further specialized and are destined to become 
specific types of cells. There are two kinds of 
hematopoietic oligolineage-restricted cells: 
common lymphocyte progenitors (CLPs) which 
are programmed to become either T or B 
lymphocytes or natural killer (NK) cells and 
common myeloid progenitors (CMPs) which are 
progenitors for myelo-erythroid lineages. CMPs 
give rise to cells that include myelomonocytic 
progenitors (GMPs) and megakaryocytic/erythroid 
progenitors (MEPs) (Figure 1). More recently, an 
impressive study has proposed a new organization 
of the hematopoiesis, suggesting a readjustment in 
the blood hierarchy during in utero to adulthood 
time points.10 Instead of a three-tiers model, the 
authors propose a two-tiers scheme in adult bone 
marrow: a top-tier which contains multipotent 
cells such as HSCs and multipotent progenitors, 
and a bottom-tier composed of committed 
unipotent progenitors (Figure 2).10 Although often 
somewhat neglected by researchers in the past, 
unipotent stem cells are unique in their ability to 
differentiate along only one cell lineage. These 
cells are found in adult tissues and comparison to 
other stem cells have the lowest differentiation 
potential.11 The potential difference between ESCs 
and ASCs can be summed up as follows: the 
former are more versatile whereas the latter are 
undifferentiated cells that are present in the 
differentiated tissue, capable of replacing cells that 
have died or lost function. ASCs have been 
identified in many different tissues including
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Figure 1. Hierarchical division of the stem cell in hematopoiesis  
 
Figure 2. Redefined model of hematopoiesis. Instead of a three-tiers model, through mulitipotent, oligopotent and then unilineage 
progenitor, the authors proposed in adult bone marrow a two-tiers scheme: a top-tier which contains multipotent cells such as HSCs and 
multipotent progenitors, and a bottom-tier composed of committed unipotent progenitors.10 
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hematopoietic (blood), epidermal, muscle, neural, 
mesenchymal, endothelial and gastrointestinal 
tissues.  
Most of the tissue-specific ASCs persist for 
prolonged periods of time in G0 phase of cell 
cycle. This quiescent state of ASCs is also referred 
to as homeostasis. Differences in the expression of 
particular genes and transcription factors 
determine the transaction from the quiescent state 
to an active phase of the cell cycle, depending on 
the organism’s needs.4 Thanks to the presence of 
telomeres, the stem cell pool maintains longevity 
and genomic stability and is protected against 
damage to DNA. Telomeres are specialized repeat 
structures of TTAGGG and nucleoprotein 
complexes localized at the ends of human 
chromosomes. These repetitive DNA sequences at 
both ends of the chromosome protect cells from 
progressive DNA shortening and degradation 
during each repeated cell division.12,13  
The fate of HSCs is also strongly influenced by 
the BM microenvironment. This 
microenvironment is composed of specialized 
microanatomical areas called niches. Numerous 
studies have shown that interactions between 
HSCs and their non-stem cell neighbors in the 
niche are critical to the maintenance of the stem 
cell pool in the quiescent state or promoting its 
self-renewal and proliferation.14 However, this 
complex network of signals that occurs in the 
niche is far from being fully elucidated.  
 
Bone Marrow Homing. Regenerative or gene 
HSC-based therapy is an interesting emerging 
field with a huge potential for the cure of 
numerous congenital and acquired diseases. There 
has been a rapid surge in clinical trials involving 
HSC therapies over the last decade. These trials 
continue to demonstrate the importance of stem 
cells both in replacing damaged tissue and in 
providing extracellular factors capable of 
promoting endogenous cellular salvage and 
replenishment.15-18  
A key feature of treatment with HSC is 
represented by their ability, once introduced into 
the bloodstream to reach their final destination in a 
distant target tissue. This intrinsic property is 
known as homing.  Homing is a crucial step 
toward successful engraftment after HSC 
transplantation. It was first described several years 
ago as an active process that allows for migration 
of HSCs through the blood and vascular 
endothelium to different organs and BM niches. 
Nevertheless, the full comprehension of this 
mechanism with its myriad of complex molecular 
events remains a challenge. Homing is a process 
that relies on intracellular signaling and interaction 
between chemokines, chemokine receptors, 
adhesion molecules, and proteases, all of which 
promote HSC adhesion to microvessels. E-
endothelial and P-endothelial selectin were found 
to be essential to cell movement (cell rolling) on 
BM microvessels (Figure 3). The intimate contact 
with chemo-attractants promotes the expression of 
HSC integrins, and through interactions with 
several members of the Ig superfamily leads to the 
cell arrest on the endothelial surface. Another 
important role in HSC homing has been assigned 
to intercellular adhesion molecule-1 (ICAM-1) 
and vascular cell adhesion molecule-1 (VCAM-1).  
These two molecules have been shown to act as 
key factors in cell trafficking between blood and 
BM.19,20 Also α4β1 integrin and lectins would seem 
to have a primary function in HSC attachment to 
marrow stromal cells.19 Several studies have 
reported that α4β1/ligand interaction contributes to 
cellular tethering and rolling.  Additionally, it has 
been shown that the homing ability of normal 
donor cells decreases after treatment with anti-
α4β1.21-23 Further evidence suggesting the 
involvement of α4β1-integrin in the homing 
process is given in the points below. 
ì) α4β1 is widely expressed in both stem and 
progenitor cells, exceeding expression of both 
L-selectin and 2-integrin taken together; 
ìì) α4β1 is constitutively active in HSC and 
progenitor cells;   
ììì) α4β1 is usually inactive in committed cells. 24-26  
The main ligand of α4β1 in committed cells is 
VCAM-1. It can, therefore, be reasonably assumed 
that all functions are likely to be accomplished 
through their interaction. However, homing 
mediated by VCAM-1 may rely on other 
pathways. 
Another important role in homing has been 
assigned to concentration of stromal-cell-derived 
factor-1 (SDF-1) ligand which increases in the BM 
microenvironment after conditioning regimens for 
HSC transplantation (Figure 4).27 SDF-1 is a 
chemokine isolated from stromal fibroblasts, and it 
is abundantly expressed by osteoblasts, endothelial 
cells and a subset of reticular cells in the 
osteoblast and vascular niches of the bone 
marrow.28 SDF-1 is highly conserved among
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Figure 3. Migration and homing of HSCs into the bone marrow microenvironment. E- endothelial and P- endothelial selectin were found to 
be important to cell movement (cell rolling) and promote weak HSC adhesion to bone marrow microvessels. The expression of the 
chemokine receptor CXCR4 on the HSC surface promotes cell activation via CXCL12 factor. Following stronger interaction between LFA-
1/ICAM-1 and VLA-4/VCAM-1, HSCs arrest on the endothelial surface and migrate through basal lamina. The migration is also promoted 
by VLA-4 and VLA-5 interaction with fibronectin, present in the extracellular matrix. 
 
Figure 4. Schematic representation of HSC homing. HSCs infused into blood are more responsive to stromal cell-derived factor (SDF)-1 
gradient between bone marrow and blood compared to other factors that are upregulated after transplantation conditioning regimen (S1P, 
ATP). 
 
species and constitutively produced in many 
tissues. At the basal homeostatic concentration, 
SDF-1 interacts as a ligand with the G-protein 
coupled receptor CXCR4, promoting HSC 
quiescence and survival. The expression of the 
chemokine receptor CXCR4 on the HSC surface 
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promotes migration and homing into or from the 
BM.29 Mouse embryos knocked out for SDF-1 or 
CXCR4 show multiple lethal defects, as well as 
the absence of BM homing by HSCs. Activation 
of the CXCR4 receptor by SDF-1 is one of the 
transductional axes most studied in recent years 
because of its fundamental importance in 
regulating trafficking of HSCs to and from the 
BM. It has also been reported that CXCR4-
depleted human cells are insensitive to 
mobilization with agonists or antagonists of the 
CXCR4 receptor.30 Secretion of SDF-1 in the bone 
marrow oscillates in a circadian manner.  This 
process, although not fully understood, also 
involves the activity of the beta3-adrenergic (AdR) 
receptor.31  
SDF-1-CXCR4 interaction triggers chemotaxis 
via intracellular GTPase proteins (heterotrimeric 
G-proteins, typically Gi subunits).32 After 
binding to SDF-1, CXCR4 undergoes down-
modulation and ubiquitination of the C-terminus 
(C-ter) by E3 ubiquitin ligase, in this way 
promoting receptor degradation or its recycling via 
the endosomal pathway.33,34 
Other potential factors involved in the homing 
process are the extracellular nucleotides (eNTPs), 
such as adenosine triphosphate (ATP) and uridine 
triphosphate (UTP), recently described as having a 
fundamental role in the modulation of HSC 
migration in the presence of SDF-1. Since 
extracellular UTP improves HSC migration 
toward SDF-1 gradients, pretreatment with eUTP, 
it is likely to increase homing of HSCs to the BM 
significantly as has been demonstrated in 
immunodeficient mice.35 The aforesaid eNTPs act 
through P2 nucleotide receptors (P2Rs); 
particularly P2YRs. These seven transmembrane-
spanning receptors, also referred to as G-protein 
coupled receptors, activate their signal 
transduction pathway via activation of 
phospholipase C or activation/inhibition of 
adenylate cyclase.36  
Although the influence of SDF-1 on HSC 
chemotactic responses has been well established,  
37,38 its role in the different molecular pathways 
underlying the early stages of homing remains a 
highly discussed and contentious issue.39,40  
Indeed, evidence has been produced of HSC 
homing to the BM independent of the SDF-1–
CXCR4 axis. Several observations support this 
evidence.  In 1999, Qing Ma and colleagues 
showed that CXCR4-deficient HSCs could 
successfully seed BM and give rise to all blood 
lineages in an SDF-1- independent manner.41 A 
study of HSC homing in a murine model made 
refractory to SDF-1 by incubation and co-injection 
with AMD3100  (a CXCR4 receptor antagonist) 
showed normal or only slightly reduced BM 
cellularity. In yet another study, HSCs in which 
CXCR4 had been knocked down using an SDF-1 
intrakine strategy were competent to engraft. 
Myeloablative conditioning for transplantation 
most likely induces a highly proteolytic BM 
microenvironment that leads to SDF-1 proteolytic 
degradation, thereby harshly sharpening its 
chemotactic homing gradient.42-44   
Adamiak and colleagues recently confirmed the 
involvement of the bioactive phosphosphingolipid 
sphingosine-1-phosphate (S1P) as a potent 
chemotactic factor for HSCs. They performed 
hematopoietic transplantation in mice deficient in 
BM-expressed sphingosine kinase 1 (Sphk1−/−), 
using HCs from normal control mice as well as 
mice in which floxed CXCR4 (CXCR4fl/fl) had 
been conditionally deleted. They found that 
homing and engraftment in the Sphk1−/− mice 
was defective after transplantation of CXCR4−/− 
BM cells, indicating that SIP expressed in the BM 
microenvironment was involved in the homing 
process.  
SIP levels in the BM are regulated by a balance 
in activity between type 1 SP-1 kinase (Sphk1) 
and S1P lyase, which has the role of degrading 
S1P.45 Since 2010, it has been observed that S1P is 
a potent chemoattractant for HSCs, much stronger 
than SDF-1.46 
It has also been suggested that HSC homing 
could be improved by inhibiting CD26 protein 
(DPPIV/dipeptidyl peptidase IV). Peptidase CD26 
removes dipeptides from the amino terminus of 
proteins, and it is has been demonstrated that 
endogenous CD26 expression on donor cells 
downregulates homing and engraftment. 
Therefore, it can be reasonably assumed that by 
deleting or inhibiting CD26, it would be possible 
to increase HSC transplantation efficiency.42 
Besides the BM microenvironment, other 
individual genetic factors can have an impact on 
successful engraftment of HSCs. For example, 
HSC homing is influenced by several molecules 
involved in inflammatory and other signaling 
pathways of innate immune response.47,48 
Ratajczak and colleagues describe how innate 
immunity derived factors are external modulators 
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of the SDF-1–CXCR4 axis. Because SDF-1 is 
extremely susceptible to degradation by 
proteolytic enzymes, its availability in biological 
fluids may be somewhat limited. However, the 
authors observed that at a minimum near threshold 
doses, SDF-1 was still able to exert a robust 
chemotactic influence on engraftment. They 
showed that chemotactic responsiveness of HSCs 
to several different types of homing gradients 
could be modulated by ex vivo manipulations, 
using a strategy that takes advantage of a 
hematopoietic stem and progenitor cell (HSPC) -
priming approach. Homing of HSPCs can be 
enhanced by ex vivo cell exposure to C3a 
(cleavage fragments of the third protein 
component of the complement cascade). A trial 
evaluating this procedure is currently ongoing at 
the Masonic Cancer Center, University of 
Minnesota.49 
Another molecule that should be tested in the 
clinical setting as a potential priming factor is 
cathelicidin LL-37, a physiological factor secreted 
by BM stromal cells with a more powerful priming 
potential than C3a.50 
Despite the many questions that still need to be 
answered, all these molecules could support a 
rationale for the development of innovative 
strategies aimed at improving HSC engraftment. 
 
Hemopoietic Stem Cell Homing and 
Engraftment Defects. Graft failure remains an 
important complication of allogeneic HSCT 
because of the high morbidity and mortality 
associated with this event. Two different clinical 
forms of defective engraftment have been 
distinguished: graft failure (GF) and poor graft 
function (PGF), both characterized by a primary or 
secondary form.51  
Graft failure is defined as absolute neutrophil 
count of 0.5 x 109/L and/or platelet count of < 20 x 
109/L. Primary graft failure is defined as failure to 
achieve absolute neutrophil count (ANC) ≥ 0.5 x 
109/L for at least 3 consecutive days or ANC 
above 0.5 × 109/L, without donor engraftment 
(autologous recovery). In secondary graft failure, 
patients fail to sustain an absolute neutrophil count 
of ≥ 0.5 x 109/L after attainment of primary donor 
engraftment or fail to sustain a platelet count of ≥ 
20 x 109/L, despite neutrophil engraftment.  
Consequently, initial donor engraftment with 
neutrophil recovery is followed by loss of the 
functioning graft.  
Both in primary and secondary graft failure, 
chimerism may vary from a full recipient status to 
a mixed condition in which donor and recipient 
cells coexist. Primary graft failure following 
myeloablative conditioning regimens generally 
determines deep and irreversible aplasia, often 
requiring re-transplantation. In secondary graft 
failure, autologous recovery is common, 
particularly after HSCT with reduced intensity 
conditioning (RIC); however, residual 
pancytopenia and bone marrow hypocellularity 
may persist.52    
From a pathogenetic viewpoint, graft failure is 
determined by the alloreactive immune responses 
of residual host immune effector cells that survive 
the conditioning regimen.51 Although the 
underlying mechanisms are not entirely known,53 it 
has been shown that residual host T cells with 
specific anti-donor or suppressive activity play a 
fundamental role, both in HLA matched and 
mismatched settings. Also, recipient natural killer 
(NK) cells are involved in the pathogenetic 
pathways leading to graft failure. Their cytotoxic 
activity against donor HSCs has been attributed to 
the inability of inhibitory killer immunoglobulin-
like receptors (KIRs) on the NK cell surface to 
recognize HLA class I molecules expressed on 
donor cells.54 On the contrary, donor regulatory T 
cells (Tregs and Tr1) and mesenchymal stem cells 
(MSC) seem to facilitate engraftment and cco-
transplantation of these cells with HSCs appears to 
have the potential to reduce the risk of graft 
failure.55-56  Donor-specific HLA antibodies have 
also been found associated with an increased risk 
of graft failure, mainly in HLA-mismatched and 
haploidentical transplantation.57-58  
Overall, the incidence of graft failure has been 
reported to be between 3 and 15%, in relation to 
the different sources of HSCs and transplant 
regimens.51,52,-59-62 Several variables have been 
investigated as potential risk factors associated 
with primary or secondary graft failure.  In a large 
retrospective study of 967 patients suffering from 
hematological malignant and non-malignant 
disorders, the parameters increasing the risk of 
graft failure were T-cell depletion, HLA-
mismatched grafts, non-malignant disorders and 
reduced-intensity conditioning. Conversely, a total 
nucleated cell dose of ≥ 2.5 x 108/kg conferred a 
reduced risk. Furthermore, primary or secondary 
graft failure was associated with lower survival 
rates in malignant than in non-malignant 
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disorders.61 Recent data, retrospectively collected 
from 4684 consecutive patients who underwent 
unrelated donor HSCT from 2006 to 2012, showed 
in univariate analysis that only the type and status 
of disease at the time of transplantation (complete 
remission versus no complete remission) were 
significant risk factors for graft failure.62  
Over the past years, umbilical cord blood 
(UCB) has increasingly been used as a source of 
HSCs for allogeneic transplantation.  Compared to 
marrow or mobilized peripheral blood stem cell 
grafts from adult donors, significant delays in 
neutrophil and platelet engraftment have been 
observed. Equally important limitations of this 
stem cell source are poor immune reconstitution 
and an increased risk of graft failure, at least partly 
due to defects in the homing capacity of these 
cells.  Poor homing of UCB cells has been 
associated with low levels of fucosylation of cell 
surface molecules that are responsible for binding 
to P- and E-selectins expressed in the BM 
microenvironment.60 Other factors linked to graft 
failure are low stem cell dose, major AB0 
incompatibility, female donor grafts for male 
recipients and myeloproliferative disease.51  
Poor graft function (PGF) is characterized by 
the presence of an initial full donor engraftment.  
In the primary form, bone marrow cellularity 
remains low, and patients present persistent 
cytopenias.51 In the secondary form, a prompt 
recovery is followed by a progressive decrease in 
blood counts.  This defect has an incidence after 
HSC transplantation ranging between 5 to 25%.63 
Several factors have been reported to be associated 
with PGF, but the most relevant condition is 
represented by graft versus host disease 
(GVHD).64 A chronic inflammatory status, with 
overexpression of cytokines such as tumor 
necrosis factor alfa (TNF-α) and interferon gamma 
(IFN-γ), may lead to a decrease in HSC renewal 
and proliferation and thus determine peripheral 
cytopenias.65,66  
Mixed chimerism (MC) after HSCT is an 
immunological condition characterized by the 
simultaneous presence of different proportions of 
both donor- and host-derived cells. This condition 
can be transient and evolve in the direction of graft 
failure or complete chimerism (CC), or persist for 
an extended period. Polymerase chain reaction 
(PCR) based on the amplification of variable 
number tandem repeats (VNTRs) or short tandem 
repeats (STRs) is currently the most common 
technique used to monitor this condition.67 In 
malignant hematological disorders, MC anticipates 
secondary graft failure and relapse.  Therefore, 
early detection of this condition is essential to 
ensure therapeutic interventions capable of 
reinforcing the graft, such as donor lymphocyte 
infusion (DLI).68    
Achievement of persistent MC in patients 
transplanted for a chronic non-malignant disease 
like thalassemia or sickle cell disease may lead to 
tolerance of donor cells toward host tissues with 
no further need for immunosuppressive therapy. 
Moreover, residual donor hematopoiesis may be 
sufficient to eliminate transfusion dependency.69-71  
After transplantation for thalassemia, MC occurs 
within the first 100 days with an overall incidence 
ranging from 30% to 45%. This condition may be 
stable or evolve to CC or rejection (secondary 
graft failure). Three levels of MC have been 
established in thalassemia with different risk 
categories for progression to rejection: 1) grade 1, 
residual host cells <10%, rejection rates of 3-12%; 
2) grade 2, residual host cells ranging between 10 - 
25%, rejection rates of 10-50%; 3) grade 3, > 25% 
residual host cells, rejection rates of 50-90%.69 
Variables reported to be associated with MC in 
thalassemia are conditioning regimens, the dose of 
infused HSCs and the severity of patient clinical 
conditions before transplantation.70  In recent 
years, it has been observed that induction of MC is 
an effective way of inducing tolerance and 
sustained graft function. Reprogramming of the 
immune system of the recipient to deliberately 
establish MC has been investigated in the solid 
organ transplant setting with the aim of improving 
the outcome and overall survival rates.71 
 
Conclusions. Homing is a fascinating mechanism 
that allows HSCs to reach the BM 
microenvironment, engraft and proliferate. This 
property has been exploited both in auto and allo 
HSC transplant settings and is currently attracting 
considerable attention in the field of gene and 
regenerative therapy. Increasing advances in gene 
delivery techniques have led to a surge of clinical 
trials over the past decade. The possibility of using 
HSCs as possible carriers of modified genes using 
viral vector delivery approaches is rapidly 
evolving. Gene therapy with HSCs has an 
enormous potential, and different clinical trials 
have resulted in functional cures for several 
inherited diseases.72 New insights on how 
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transplanted HSCs can reach the BM and which 
factors influence the homing process are thus 
critical.  
Graft failure continues to be a major contributor 
to morbidity and mortality after allogeneic HSCT 
in patients with malignant and non-malignant 
diseases, particularly when treated with reduced-
intensity conditioning regimens or grafts from 
HLA-mismatched donors. Such cases require close 
surveillance and regular monitoring of chimerism. 
On the other hand, deliberate induction of mixed 
chimerism by modulating the host immune system 
could represent an attractive way to improve graft 
survival in the future. 
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